During infection, pathogenic bacteria manipulate the host cell in various ways to allow their own replication, propagation and escape from host immune responses. Post-translational modifications are unique mechanisms that allow cells to rapidly, locally and specifically modify activity or interactions of key proteins. Some of these modifications, including phosphorylation and ubiquitylation 1,2 , can be induced by pathogens. However, the effects of pathogenic bacteria on SUMOylation, an essential post-translational modification in eukaryotic cells 3 , remain largely unknown. Here we show that infection with Listeria monocytogenes leads to a decrease in the levels of cellular SUMO-conjugated proteins. This event is triggered by the bacterial virulence factor listeriolysin O (LLO), which induces a proteasome-independent degradation of Ubc9, an essential enzyme of the SUMOylation machinery, and a proteasomedependent degradation of some SUMOylated proteins. The effect of LLO on Ubc9 is dependent on the pore-forming capacity of the toxin and is shared by other bacterial pore-forming toxins like perfringolysin O (PFO) and pneumolysin (PLY). Ubc9 degradation was also observed in vivo in infected mice. Furthermore, we show that SUMO overexpression impairs bacterial infection. Together, our results reveal that Listeria, and probably other pathogens, dampen the host response by decreasing the SUMOylation level of proteins critical for infection.
During infection, pathogenic bacteria manipulate the host cell in various ways to allow their own replication, propagation and escape from host immune responses. Post-translational modifications are unique mechanisms that allow cells to rapidly, locally and specifically modify activity or interactions of key proteins. Some of these modifications, including phosphorylation and ubiquitylation 1, 2 , can be induced by pathogens. However, the effects of pathogenic bacteria on SUMOylation, an essential post-translational modification in eukaryotic cells 3 , remain largely unknown. Here we show that infection with Listeria monocytogenes leads to a decrease in the levels of cellular SUMO-conjugated proteins. This event is triggered by the bacterial virulence factor listeriolysin O (LLO), which induces a proteasome-independent degradation of Ubc9, an essential enzyme of the SUMOylation machinery, and a proteasomedependent degradation of some SUMOylated proteins. The effect of LLO on Ubc9 is dependent on the pore-forming capacity of the toxin and is shared by other bacterial pore-forming toxins like perfringolysin O (PFO) and pneumolysin (PLY). Ubc9 degradation was also observed in vivo in infected mice. Furthermore, we show that SUMO overexpression impairs bacterial infection. Together, our results reveal that Listeria, and probably other pathogens, dampen the host response by decreasing the SUMOylation level of proteins critical for infection.
L. monocytogenes is a facultative intracellular pathogen responsible for human listeriosis, a severe food-borne disease, and has emerged as a model for the study of host-pathogen interactions 4 . This bacterium is able to cross the intestinal, maternofetal and blood-brain barriers, to resist macrophage killing and to enter into normally non-phagocytic cells and replicate therein. During infection, L. monocytogenes exploits an amazingly high number of mammalian cell functions for its own benefit. In particular, Listeria interferes with several signalling pathways and is able to regulate host protein activities by modifying their ubiquitylation or phosphorylation [5] [6] [7] . However, the impact of L. monocytogenes on SUMOylation, an essential post-translational modification, remains completely unknown.
SUMOylation is a reversible modification in which SUMO, an ubiquitin-like polypeptide of approximately 10 kDa, is covalently linked to target proteins. This conjugation results from the formation of an isopeptide bond between the carboxy-terminal Gly residue of a mature SUMO moiety and a Lys side chain of the substrate protein 3 . The human genome encodes three functional SUMO isoforms that can be linked to distinct and overlapping sets of proteins 8 . Covalent linkage of SUMO to its substrate requires a set of different enzymes, in an analogous fashion to ubiquitylation. In humans, the SUMOylation machinery is composed of an E1 SUMO enzyme (the SAE1/SAE2 heterodimer), an E2 SUMO enzyme (Ubc9) and E3 SUMO enzymes that enhance SUMO conjugation of specific targets. In contrast to the ubiquitylation machinery in which several dozen E2 enzymes are found 9 , the E2 SUMO enzyme is unique in mammals and is required for viability 10 . The SUMOylation level of cellular proteins is tightly regulated by SUMO-specific proteases that catalyse the deconjugation of SUMO from its substrates 11 . SUMOylation, like ubiquitylation, is essential for different cellular functions. Several hundreds of SUMO targets have now been identified, involved in transcription regulation, maintenance of genome integrity, intracellular transport, stress responses, protein stability and many other biological processes (for review, see refs 3, 12) .
Interestingly, some viruses interfere with the SUMOylation of host proteins 13 . We thus tested the hypothesis that pathogenic bacteria, like viruses, also alter host protein SUMOylation for the orchestration of the onset, establishment and/or persistence of the infectious process, and addressed this issue in the case of infection with L. monocytogenes.
To investigate whether L. monocytogenes was able to modify SUMOylation of host cell proteins upon infection, we compared the global pattern of proteins conjugated to SUMO1 or SUMO2/3 in uninfected cells with that of cells infected by L. monocytogenes or incubated with Listeria innocua, a non-pathogenic Listeria species. HeLa cells infected with L. monocytogenes displayed, after 3 h of infection, a decrease in both SUMO1-and SUMO2/3-conjugated proteins of high molecular mass, compared with uninfected cells (Fig. 1a) . This decrease was not observed with L. innocua and is thus specific to the pathogenic L. monocytogenes species. This global reduction in protein SUMOylation was confirmed by proteomic analysis of SUMO-conjugated proteins isolated from cells infected or not by L. monocytogenes, using the stable isotope labelling of amino acids in cell culture technique (SILAC) 14 (Supplementary Fig. 1 and Supplementary Tables 1 and 2 ). A decrease in SUMOylated proteins upon infection with Listeria is of particular interest as it clearly differs from the reported increase in SUMOylation observed for cells subjected to various environmental stresses 15, 16 . A Listeria DinlB mutant impaired in entry into HeLa cells still induced a decrease in SUMO-conjugated proteins (Fig. 1b) , indicating that this decrease can be triggered by extracellular bacteria, and involves a surface or secreted protein. We thus tested a Listeria Dhly mutant, defective for LLO, a secreted pore-forming toxin with a potent signalling activity, involved in the escape of Listeria from the internalization vacuole 17 . Strikingly, this mutant had no effect on host SUMOylated proteins (Fig. 1b) , which strongly suggested that LLO plays a role in the decrease in SUMOylation observed with wild-type Listeria. We next analysed the global SUMOylation pattern of cells incubated with purified LLO alone, at a non-cytotoxic concentration 7 . LLO was sufficient to trigger a massive decrease in SUMOylated proteins in the host cell, both for SUMO1 and SUMO2/3 isoforms (Fig. 1c) . This effect was not restricted to HeLa cells and was observed in Jeg3 cells (Supplementary Fig. 2 ).
As many different SUMO targets were affected, we hypothesized that LLO could have an effect on the SUMOylation machinery. In vitro SUMOylation of RanGAP1, a well-characterized SUMO substrate 18 , was not affected by adding increasing amounts of LLO in the reaction, revealing that LLO has no direct inhibitory effect on E1 or E2 SUMO enzymes (Fig. 2a) . We then quantified the levels of E1 or E2 SUMO enzymes in HeLa cells incubated with purified LLO. Strikingly, LLO induced a dramatic decrease in the level of Ubc9, in a dose-dependent manner, whereas the levels of SAE1 and SAE2 remained unaffected (Fig. 2b, d ). The messenger RNA levels of Ubc9 were not affected upon LLO incubation (Supplementary Fig. 3 ). Moreover, LLO strongly reduced Ubc9 half-life (from more than 8 h to less than 10 min), and inhibition of cellular protein synthesis by cycloheximide did not prevent the LLO-triggered decrease in Ubc9 levels (Fig. 2b, c and Supplementary Fig. 3 ). Together, these results indicate that LLO does not affect Ubc9 translation but rather triggers its degradation. To our knowledge, LLO is the first bacterial factor inducing the degradation of the E2 SUMO enzyme. The decrease in Ubc9 level triggered by LLO was also observed during bacterial infection of HeLa and Jeg3 cells but was not observed in cells infected with a L. monocytogenes Dhly mutant (Fig. 2e, f and Supplementary Fig. 2) .
To determine whether LLO pore formation is required to trigger Ubc9 degradation, we first preincubated LLO with A4-8, a monoclonal antibody preventing the binding of the toxin to cellular membranes 19 . This preincubation impaired the LLO-dependent decrease in Ubc9 levels in HeLa cell extracts, indicating that binding of the toxin to membranes is required for Ubc9 targeting (Fig. 3a) . We then monitored the effect of three different LLO variants able to bind cellular membranes but affected in their haemolytic activities (Supplementary 21 . Analysis of HeLa cells incubated with these three LLO mutants revealed a correlation between the haemolytic activities of the mutants and degradation of Ubc9 (Fig. 3b) . Together, these data reveal that both binding of LLO to cellular membranes and pore formation are required to trigger Ubc9 degradation.
To determine whether the effect of LLO on Ubc9 is a property shared by other pore-forming toxins, we analysed the effect of PFO and PLY, two toxins of the same family as LLO, encoded by two other bacterial pathogens (Clostridium perfringens and Streptococcus pneumoniae, respectively). Interestingly, like LLO, PFO and PLY triggered a degradation of Ubc9 (Fig. 3c) . Thus, other pathogenic bacteria, including extracellular pathogens, can target the SUMOylation machinery with mechanisms similar to that used by Listeria.
To identify the mechanisms underlying Ubc9 degradation, we used different pharmacological inhibitors. Inhibition of proteasome activity by MG132 has no effect on the level of Ubc9, which still decreased in HeLa cells upon incubation with LLO (Fig. 3d) . As a control, we verified that HeLa cells expressing Gam1, a viral protein triggering the proteasomal degradation of SAE1, SAE2 and Ubc9 22, 23 , displayed a reduction in the levels of these enzymes compared with control cells, whereas MG132-treated cells did not (Fig. 3d) . Together, these data indicate that LLO-induced Ubc9 degradation is proteasome-independent and highlight differences in the mechanism of action of LLO and Gam1, although both proteins target the host cell SUMOylation machinery. Previous reports have shown that LLO can activate different signalling pathways through triggering of calcium influx from the extracellular medium and activation of mitogen-activated protein kinases (MAPKs) 17, 24, 25 . We showed that LLOmediated Ubc9 degradation is independent of the calcium influx triggered by LLO and independent of p38 or ERK activities (Supplementary Fig. 4) . In contrast, pepstatin-A-methylester, a cell permeable aspartyl-protease inhibitor, was able to partly impair Ubc9 decrease (Fig. 3e) . The effect of pepstatin-A-methylester on LLO-induced Ubc9 degradation seems specific as it had no effect on histone H3 Ser 10 dephosphorylation, another LLO-induced modification 7 . Together, our results strongly suggest that the LLOmediated Ubc9 degradation is induced through a non-classical pathway, which involves an aspartyl-protease remaining to be identified.
We then focused on the downstream effects of Ubc9 degradation. We hypothesized that degradation of Ubc9 is a key event that not only triggers a blockade of SUMOylation but also leads to the deSUMOylation of SUMO-conjugated proteins owing to the activity of deSUMOylases. Consistently, whereas the total level of RanGAP1 protein (that is, SUMO*RanGAP11RanGAP1 in Fig. 3f ) remains mostly unchanged upon LLO treatment in HeLa cells, the quantity of unSUMOylated RanGAP1 significantly increases, in agreement with a deSUMOylation of this target (Fig. 3f) . However, one cannot exclude that the observed decrease in some SUMO-conjugated proteins might also be due to degradation, rather than deSUMOylation. Indeed, inhibition of the proteasome partly abrogates the decrease in SUMO-conjugated proteins triggered by LLO (approximately 50% inhibition, Fig. 3g ). We thus conclude that LLO triggers both a global deSUMOylation event and degradation of some SUMO-conjugated proteins.
To investigate further the downstream effects of the LLOmediated decrease in SUMO-conjugated host proteins, we selected as a read-out the transforming growth factor b (TGF-b) response of the cell, a pathway regulated by SUMOylation. Indeed, SUMOylation stabilizes SMAD4, a central intracellular signal transducer for TGF-b signalling 26 and regulates the TGF-b receptor TbR1 27 . We first observed that infection with wild-type L. monocytogenes, as well as incubation with LLO, leads to a decrease in SMAD4 level, in agreement with the reported role of SUMOylation in SMAD4 stabilization (Fig. 4a, b ). This decrease in SMAD4 level was not observed in cells infected with a Listeria Dhly mutant (Fig. 4a) . Overexpression of SUMO1 in HeLa cells counteracted the decrease in SMAD4 induced by LLO, thus confirming that this decrease is linked to the effect of the toxin on the SUMOylation of host proteins (Fig. 4b) . We then quantified the capacity of cells infected by Listeria to respond to TGF-b by using a reporter plasmid encoding luciferase under the control of SMAD transcriptional response elements. TGF-b response of infected 293FT cells was strongly impaired compared with noninfected cells or cells infected with a Listeria Dhly mutant (Fig. 4c) . Together, these results suggest that loss of SUMO-conjugated proteins upon L. monocytogenes infection affects the TGF-b response of the host cell. However, we cannot rule out that other pathways affected by LLO might participate in the observed impairment of TGF-b response in infected cells. Of note, TGF-b is known to play a role in pathogen infections 28 and, in particular, it has been proposed to have a protective role in host resistance against infection with L. monocytogenes 29 . Impairment of TGF-b signalling might thus be beneficial for Listeria to replicate and disseminate in its host.
To characterize the putative role of SUMOylation during infection, we increased the level of SUMOylated proteins in HeLa cells by overexpressing SUMO1 or SUMO2 (Fig. 4d) . We infected these cells with L. monocytogenes and determined the number of intracellular bacteria 7 h after infection. This number was significantly reduced in cells overexpressing SUMO1 or SUMO2 compared with control cells (Fig. 4e) . Thus, induction of an increase in SUMOylation is detrimental for bacterial invasion and/or replication. Conversely, Ubc9 degradation triggered by L. monocytogenes is probably important to promote bacterial infection by lowering SUMOylation of different host proteins.
To examine the relevance of our in vitro data during infection, we tested whether Ubc9 degradation observed in tissue-cultured cells was also detectable in vivo. Quantification of Ubc9 levels in livers of C57Bl/6J mice infected with L. monocytogenes showed a significant reduction at 48 h and 72 h after infection (Fig. 4f) . Thus, Ubc9 degradation occurs in vivo in organs infected by L. monocytogenes.
In conclusion, we report here a previously unknown strategy used by Listeria to promote its infection capacity. By targeting an essential enzyme of the SUMO pathway, L. monocytogenes has developed an efficient strategy to modify simultaneously activity of many different proteins of the host cell. That toxins produced by other pathogens also induced Ubc9 degradation highlights that inhibition of SUMOylation by pathogens may be a widespread phenomenon.
METHODS SUMMARY
Plasmids, bacterial strains, antibodies, cell culture and transfection conditions are described in the Methods. For in vitro infections, bacteria were added to HeLa, Jeg3 or 293FT cells at a multiplicity of infection of 50. After 1 h of infection, cells were incubated with 10 mg ml 21 gentamicin to kill extracellular bacteria. Quantification of intracellular bacteria was performed by plating bacteria released from infected cells lysed in PBS-Triton X-100 0.2%. For in vivo infection, 10 6 bacteria were injected intravenously to C57Bl/6J mice. Livers of mice were then collected and lysed as described in the Methods before immunoblotting experiments. LLO, PFO and PLY proteins were added directly in the culture medium of cells as indicated. Immunoblotting experiments were performed as described in the Methods. All displayed immunoblots are representative of at least three independent experiments. Quantification of immunoblots was performed using a G:Box Gel documentation system (Syngene). In vitro SUMOylation assays were performed using the BioMol SUMOylation kit according to the manufacturer's protocol. Luciferase activities were quantified on a Tristar LB491 luminometer (Berthold Technologies) using the Dual Luciferase Assay (Promega). Means 6 standard deviations are shown in the figures and P values were calculated using a two-tailed two-sample equal variance Student's t-test.
Full Methods and any associated references are available in the online version of the paper at www.nature.com/nature.
